Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Current Leases (2019 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Current Leases for 7 consecutive years, with $650000.0 as the latest value for Q4 2025.

  • Quarterly Current Leases changed N/A to $650000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $650000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $650000.0 for FY2025, N/A changed from the prior year.
  • Current Leases for Q4 2025 was $650000.0 at Rhythm Pharmaceuticals, up from $624000.0 in the prior quarter.
  • The five-year high for Current Leases was $816000.0 in Q2 2024, with the low at $224000.0 in Q1 2025.
  • Average Current Leases over 5 years is $638888.9, with a median of $647000.0 recorded in 2022.
  • The sharpest move saw Current Leases grew 13.55% in 2021, then plummeted 71.75% in 2025.
  • Over 5 years, Current Leases stood at $606000.0 in 2021, then increased by 12.87% to $684000.0 in 2022, then increased by 12.57% to $770000.0 in 2023, then grew by 5.97% to $816000.0 in 2024, then dropped by 20.34% to $650000.0 in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $650000.0, $624000.0, and $510000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.